324 related articles for article (PubMed ID: 11106752)
21. Targeting the acute promyelocytic leukemia-associated fusion proteins PML/RARα and PLZF/RARα with interfering peptides.
Beez S; Demmer P; Puccetti E
PLoS One; 2012; 7(11):e48636. PubMed ID: 23152790
[TBL] [Abstract][Full Text] [Related]
22. RARα-PLZF oncogene inhibits C/EBPα function in myeloid cells.
Girard N; Tremblay M; Humbert M; Grondin B; Haman A; Labrecque J; Chen B; Chen Z; Chen SJ; Hoang T
Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13522-7. PubMed ID: 23898169
[TBL] [Abstract][Full Text] [Related]
23. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
[TBL] [Abstract][Full Text] [Related]
24. Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein.
Li JY; English MA; Ball HJ; Yeyati PL; Waxman S; Licht JD
J Biol Chem; 1997 Sep; 272(36):22447-55. PubMed ID: 9278395
[TBL] [Abstract][Full Text] [Related]
25. UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia.
Kitareewan S; Pitha-Rowe I; Sekula D; Lowrey CH; Nemeth MJ; Golub TR; Freemantle SJ; Dmitrovsky E
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3806-11. PubMed ID: 11891284
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC.
Rice KL; Hormaeche I; Doulatov S; Flatow JM; Grimwade D; Mills KI; Leiva M; Ablain J; Ambardekar C; McConnell MJ; Dick JE; Licht JD
Blood; 2009 Dec; 114(27):5499-511. PubMed ID: 19855079
[TBL] [Abstract][Full Text] [Related]
27. [Effects of arsenic trioxide on K562 cells stably expressing two promyelocytic leukemia-specific fusion proteins].
Zhou L; Chen G; Pan L
Zhonghua Yi Xue Za Zhi; 2000 Apr; 80(4):297-300. PubMed ID: 11798775
[TBL] [Abstract][Full Text] [Related]
28. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Lo-Coco F; Hasan SK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
[TBL] [Abstract][Full Text] [Related]
29. The theory of APL.
Piazza F; Gurrieri C; Pandolfi PP
Oncogene; 2001 Oct; 20(49):7216-22. PubMed ID: 11704849
[TBL] [Abstract][Full Text] [Related]
30. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling.
Ruthardt M; Testa U; Nervi C; Ferrucci PF; Grignani F; Puccetti E; Grignani F; Peschle C; Pelicci PG
Mol Cell Biol; 1997 Aug; 17(8):4859-69. PubMed ID: 9234742
[TBL] [Abstract][Full Text] [Related]
31. Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia.
Hummel JL; Wells RA; Dubé ID; Licht JD; Kamel-Reid S
Oncogene; 1999 Jan; 18(3):633-41. PubMed ID: 9989813
[TBL] [Abstract][Full Text] [Related]
32. Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways.
Dong S; Tweardy DJ
Blood; 2002 Apr; 99(8):2637-46. PubMed ID: 11929748
[TBL] [Abstract][Full Text] [Related]
33. 8-CPT-cAMP/all-trans retinoic acid targets t(11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF/RARα degradation.
Jiao B; Ren ZH; Liu P; Chen LJ; Shi JY; Dong Y; Ablain J; Shi L; Gao L; Hu JP; Ren RB; de Thé H; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3495-500. PubMed ID: 23382200
[TBL] [Abstract][Full Text] [Related]
34. Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A.
Yeyati PL; Shaknovich R; Boterashvili S; Li J; Ball HJ; Waxman S; Nason-Burchenal K; Dmitrovsky E; Zelent A; Licht JD
Oncogene; 1999 Jan; 18(4):925-34. PubMed ID: 10023668
[TBL] [Abstract][Full Text] [Related]
35. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications.
He LZ; Merghoub T; Pandolfi PP
Oncogene; 1999 Sep; 18(38):5278-92. PubMed ID: 10498880
[TBL] [Abstract][Full Text] [Related]
36. Modeling acute promyelocytic leukemia in the mouse: new insights in the pathogenesis of human leukemias.
Merghoub T; Gurrieri C; Piazza F; Pandolfi PP
Blood Cells Mol Dis; 2001; 27(1):231-48. PubMed ID: 11358384
[TBL] [Abstract][Full Text] [Related]
37. Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia.
Guo Y; Dolinko AV; Chinyengetere F; Stanton B; Bomberger JM; Demidenko E; Zhou DC; Gallagher R; Ma T; Galimberti F; Liu X; Sekula D; Freemantle S; Dmitrovsky E
Cancer Res; 2010 Dec; 70(23):9875-85. PubMed ID: 20935222
[TBL] [Abstract][Full Text] [Related]
38. Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein.
Dong S; Zhu J; Reid A; Strutt P; Guidez F; Zhong HJ; Wang ZY; Licht J; Waxman S; Chomienne C; Chen Z; Zelent A; Chen SJ
Proc Natl Acad Sci U S A; 1996 Apr; 93(8):3624-9. PubMed ID: 8622986
[TBL] [Abstract][Full Text] [Related]
39. Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia.
Pandolfi PP
Hum Mol Genet; 2001 Apr; 10(7):769-75. PubMed ID: 11257111
[TBL] [Abstract][Full Text] [Related]
40. Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains.
Grignani F; Testa U; Rogaia D; Ferrucci PF; Samoggia P; Pinto A; Aldinucci D; Gelmetti V; Fagioli M; Alcalay M; Seeler J; Grignani F; Nicoletti I; Peschle C; Pelicci PG
EMBO J; 1996 Sep; 15(18):4949-58. PubMed ID: 8890168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]